Viral Destruction: Sponsored Q&A by Microthermics - - BioPharm International

ADVERTISEMENT

Viral Destruction: Sponsored Q&A by Microthermics


A range of industries—biotechnology, food and pharmaceuticals—must keep viral contamination out of their products. To do this effectively, a company needs a reliable, continuous process, and one that can be scaled to the company’s specific needs. To explore these topics, BioPharm International talked with John Miles, PhD, president and founder of MicroThermics Inc. This company specializes in small-scale solutions in high-temperature short-time (HTST) and ultra-high temperature (UHT) processes.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here